CEA (CEACAM5) expression is common in muscle-invasive urothelial carcinoma of the bladder but unrelated to the disease course.
Henning PlageKira FurlanoJörg NeymeyerSarah WeinbergerBenedikt GerdesMandy HubatschBernhard RallaAntonia FranzAnnika FendlerMichela de MartinoFlorian RoßnerSimon SchallenbergSefer ElezkurtajMartina KluthMaximilian LennartzNiclas C BlessinAndreas H MarxHenrik SamtlebenMargit FischMichael RinkKrystian KaczmarekThorsten EckeSteffen HallmannStefan KochNico AdaminiSarah MinnerRonald SimonGuido SauterJoachim WeischenfeldtTobias KlatteThorsten SchlommDavid HorstHenrik ZechaMarcin SlojewskiPublished in: BJUI compass (2024)
CEA increases markedly with grade progression in pTa tumours, and expression occurs in a significant fraction of pT2-4 urothelial bladder carcinomas. The high rate of CEA positivity in pT2-4 carcinomas offers the opportunity of using CEA serum measurement for monitoring the clinical course of these cancers. Moreover, CEA positive urothelial carcinomas are candidates for a treatment by targeted anti-CEA drugs.